

Supplementary material for Maringe C. et al. Stage at diagnosis and colorectal cancer survival in six high-income countries: A population-based study of patients diagnosed during 2000–2007, Acta Oncologica, 2013;52:919–932.

Supplementary Appendix 1

*ICBP Module 1 Working Group

Programme Board: Søren Brostrøm (Danish National Board of Health, Hospital Services and Emergency Management, Copenhagen, Denmark); Heather Bryant (Canadian Partnership Against Cancer, Toronto, Ontario, Canada); David Currow (Cancer Institute New South Wales, Sydney, New South Wales, Australia); Anna Gavin (Northern Ireland Cancer Registry, Belfast, UK); Gunilla Gunnarsson (Swedish Association of Local Authorities and Regions, Stockholm, Sweden); Jane Hanson (Cancer National Specialist Advisory Group, Wales, UK); Todd Harper (Cancer Council Victoria, Carlton, Victoria, Australia); Stein Kaasa (University Hospital of Trondheim, Trondheim, Norway); Michael A. Richards (National Cancer Action Team, Department of Health, London, UK); Michael Sherar (Cancer Care Ontario, Toronto, Ontario, Canada); Bob Thomas (Department of Health Victoria, Melbourne, Victoria, Australia).

Module 1 Collaborators and Cancer Registries: Jan Adolfsson (Regional Cancer Centre, Stockholm County Council and the CLINTEC Department, Karolinska Institutet, Stockholm, Sweden); Ole Andersen (National Board of Health, Health Planning Division, Copenhagen, Denmark); Heather Bryant (Canadian Partnership Against Cancer, Toronto, Ontario, Canada); Andy Coldman (Cancer Surveillance and Outcomes, British Columbia Cancer Agency, Vancouver, British Columbia, Canada); Dhali Dhaliwal (CancerCare Manitoba, Winnipeg, Manitoba, Canada); Gerda Engholm (Department of Cancer Prevention and Documentation, Danish Cancer Society, Copenhagen, Denmark); David Forman (Section of Cancer Information, International Agency for Research on Cancer, Lyon, France); Marianne L. Gjerstorff (Danish Cancer Registry, Statens Serum Institut, National Institute for Health Data and Disease Control, Copenhagen, Denmark); Juanita Hatcher (Alberta Health Services, Edmonton, Alberta, Canada); Charlotte Hosbond (National Board of Health, Copenhagen, Denmark); Tom B. Johannesen (Norwegian Cancer Registry, Oslo, Norway); Mats Lambe (Regional Oncological Centre, Uppsala University Hospital, Uppsala, Sweden and the Karolinska Institutet, Stockholm, Sweden); Loraine Marrett (Cancer Care Ontario, Toronto, Ontario, Canada); Colleen E. McGahan

(Cancer Surveillance and Outcomes, British Columbia Cancer Agency, Vancouver, British Columbia, Canada); John McLaughlin (Cancer Care Ontario, Toronto, Ontario, Canada); David Meechan (Trent Cancer Registry, Sheffield, UK); Richard Middleton (Northern Ireland Cancer Registry, Belfast, UK); Kamini Milnes (Cancer Care Ontario, Toronto, Ontario, Canada); Eva Morris (University of Leeds and Northern and Yorkshire Cancer Registration and Information Service, Leeds, UK); Diane Nishri (Cancer Care Ontario, Toronto, Ontario, Canada); Nicola Quin (Cancer Council Victoria, Carlton, Victoria, Australia); Linda Rabenek (Cancer Care Ontario, Toronto, Ontario, Canada); Carol Russell (Alberta Health Services, Edmonton, Alberta, Canada); Janey Shin (Canadian Partnership Against Cancer, Toronto, Ontario, Canada); John Steward (Welsh Cancer Intelligence and Surveillance Unit, Cardiff, Wales, UK); James Thomas (Northern and Yorkshire Cancer Registration and Information Service, Leeds, UK); Elizabeth Tracey (Cancer Institute New South Wales, Sydney, New South Wales, Australia); Donna Turner (CancerCare Manitoba, Winnipeg, Manitoba, Canada).

Clinical Committee: John Butler (St Bartholomew's and Royal Marsden Hospitals, London, UK); Tony Fields (University of Alberta, Edmonton, Alberta, Canada); Paul Finan (University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, UK); Anders Fisher (Department of Surgical Gastroenterology, University of Copenhagen, Gentofte Hospital, Hellerup, Denmark); Tim Maughan (Velindre NHS Trust, Cardiff, UK); Roy Maxwell (Royal Victoria Hospital, Belfast, UK); Bjørn Nedrebø (Stavanger University Hospital, Stavanger, Norway); Lars Pählman (Department of Surgical Sciences, Uppsala University, Uppsala, Sweden); Andrew Radcliffe (Llandough Hospital, Penarth, Wales, UK); Annika Sjövall (Karolinska University Hospital, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden); Allan Spigelman (University of New South Wales, St Vincent's Clinical School & Cancer Services, St Vincent's & Mater Health, The Kinghorn Cancer Centre, Sydney, New South Wales, Australia).

Central Analytic Team: Camille Maringe, Sarah Walters, Bernard Rachet, Michel P. Coleman (Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK).

Supplementary Tables and Figures

Supplementary Table I Stage-specific sets of weights used for age standardisation of colon cancer estimates

Supplementary Table II Stage-specific sets of weights used for age standardisation of rectal cancer estimates

Supplementary Figure I Proportions of colon cancer patients with missing data on stage (upper figure) and cumulative stage distribution (lower figure) by age at diagnosis and country, Dukes' (left) and SEER Summary Stage 2000 (right)

Supplementary Table III All-ages, age-specific and age-standardised three-year net survival (%) by stage at diagnosis, age and country for colon cancer patients diagnosed during 2000–2007

Supplementary Table IV All-ages, age-specific and age-standardised three-year net survival (%) by stage at diagnosis, age and country for rectal cancer patients diagnosed during 2000–2007

Supplementary Figure II Age-standardised three-year net survival from colon cancer by stage at diagnosis and country using known stage and imputed stage, Dukes' (upper figure) and SEER Summary Stage 2000 (lower figure)

Supplementary Figure III Age-standardised three-year net survival from rectal cancer by stage at diagnosis and country using known stage and imputed stage, Dukes' (upper figure) and SEER Summary Stage 2000 (lower figure)

Supplementary Tables

Supplementary Table I. Stage-specific sets of weights used for age standardisation of colon cancer estimates.

Dukes' stage	Age category	Weights	SEER Summary Stage 2000	Age category	Weights
All patients	15–44	0.03	All patients	15–44	0.03
	45–54	0.06		45–54	0.06
	55–64	0.16		55–64	0.17
	65–74	0.29		65–74	0.29
	75–84	0.34		75–84	0.33
	85–99	0.13		85–99	0.12
Dukes' stage A	15–44	0.02	Localised	15–44	0.02
	45–54	0.06		45–54	0.06
	55–64	0.17		55–64	0.16
	65–74	0.32		65–74	0.30
	75–84	0.34		75–84	0.36
	85–99	0.08		85–99	0.10
Dukes' stage B	15–44	0.02	Regional	15–44	0.03
	45–54	0.05		45–54	0.07
	55–64	0.15		55–64	0.18
	65–74	0.30		65–74	0.30
	75–84	0.36		75–84	0.32
	85–99	0.11		85–99	0.10
Dukes' stage C	15–44	0.03	Distant	15–44	0.03
	45–54	0.07		45–54	0.08
	55–64	0.19		55–64	0.19
	65–74	0.31		65–74	0.29
	75–84	0.32		75–84	0.30
	85–99	0.09		85–99	0.10
Dukes' stage D	15–44	0.03	Missing stage	15–44	0.03
	45–54	0.08		45–54	0.05
	55–64	0.19		55–64	0.13
	65–74	0.30		65–74	0.24
	75–84	0.30		75–84	0.35
	85–99	0.10		85–99	0.21
Missing stage	15–44	0.03			
	45–54	0.05			
	55–64	0.13			
	65–74	0.24			
	75–84	0.35			
	85–99	0.21			

Supplementary Table II. Stage-specific sets of weights used for age standardisation of rectal cancer estimates

Dukes' stage	Age category	Weights	SEER Summary Stage 2000	Age category	Weights
All patients	15–44	0.03	All patients	15–44	0.03
	45–54	0.08		45–54	0.09
	55–64	0.21		55–64	0.21
	65–74	0.30		65–74	0.30
	75–84	0.28		75–84	0.28
	85–99	0.09		85–99	0.09
Dukes' stage A	15–44	0.03	Localised	15–44	0.02
	45–54	0.08		45–54	0.08
	55–64	0.22		55–64	0.22
	65–74	0.33		65–74	0.32
	75–84	0.28		75–84	0.28
	85–99	0.07		85–99	0.07
Dukes' stage B	15–44	0.02	Regional	15–44	0.03
	45–54	0.08		45–54	0.10
	55–64	0.21		55–64	0.24
	65–74	0.32		65–74	0.31
	75–84	0.30		75–84	0.26
	85–99	0.07		85–99	0.05
Dukes' stage C	15–44	0.03	Distant	15–44	0.04
	45–54	0.10		45–54	0.11
	55–64	0.24		55–64	0.23
	65–74	0.32		65–74	0.30
	75–84	0.26		75–84	0.26
	85–99	0.05		85–99	0.07
Dukes' stage D	15–44	0.03	Missing stage	15–44	0.02
	45–54	0.10		45–54	0.07
	55–64	0.23		55–64	0.16
	65–74	0.30		65–74	0.25
	75–84	0.26		75–84	0.31
	85–99	0.07		85–99	0.18
Missing stage	15–44	0.02			
	45–54	0.07			
	55–64	0.17			
	65–74	0.25			
	75–84	0.31			
	85–99	0.18			

Supplementary Table III. All-ages, age-specific and age-standardised three-year net survival (%) by stage at diagnosis, age and country for colon cancer patients diagnosed during 2000–2007

		Australia ¹			Canada ^{2,5}			Denmark ⁵			Norway			Sweden ³			UK ⁴		
		NS (%)	95% CI		NS (%)	95% CI		NS (%)	95% CI		NS (%)	95% CI		NS (%)	95% CI		NS (%)	95% CI	
Dukes' stage																			
All patients	All ages				62.8	61.1 64.5		58.1	56.8 59.5					68.1	67.1 69.1		54.9	54.6 55.2	
	Age-standardised				62.2	61.0 63.4		57.7	56.7 58.7					68.2	67.4 69.0		54.9	54.7 55.1	
	15–49				70.0	65.8 74.2		66.9	62.5 71.2					71.0	67.6 74.4		65.1	64.1 66.1	
	50–69				67.9	65.7 70.1		64.9	63.1 66.7					70.1	68.7 71.6		62.0	61.6 62.5	
	70–99				58.6	56.4 60.8		53.4	51.7 55.1					66.9	65.5 68.2		50.4	50.0 50.7	
Dukes' stage A	All ages				94.0	91.0 97.1		88.8	84.8 92.7					98.2	96.7 99.8		94.9	94.1 95.7	
	Age-standardised				94.0	91.9 96.1		88.7	85.8 91.6					98.4	97.5 99.3		94.9	94.2 95.5	
	15–49				96.7	90.5 100.0		98.2	94.5 100.0					99.7	98.4 100.0		96.7	95.1 98.3	
	50–69				96.1	93.4 98.8		93.1	89.4 96.8					98.7	96.7 100.0		95.9	95.1 96.7	
	70–99				92.4	87.8 97.0		85.6	79.8 91.4					97.9	96.2 99.7		94.2	92.9 95.4	
Dukes' stage B	All ages				87.3	84.7 89.9		87.0	84.6 89.3					91.3	90.0 92.6		84.8	84.3 85.3	
	Age-standardised				87.1	85.7 88.5		86.8	85.6 88.1					91.5	90.8 92.2		84.8	84.4 85.2	
	15–49				91.7	89.7 93.7		91.5	89.7 93.4					94.6	93.6 95.7		90.1	88.9 91.4	
	50–69				90.1	88.1 92.2		89.6	87.7 91.5					93.5	92.4 94.5		88.1	87.5 88.6	
	70–99				85.3	82.4 88.3		85.2	82.5 87.8					90.3	88.8 91.8		82.8	82.1 83.5	
Dukes' stage C	All ages				70.5	67.2 73.9		67.2	64.3 70.0					68.7	66.7 70.7		58.2	57.6 58.8	
	Age-standardised				70.7	68.2 73.2		66.5	64.4 68.7					69.6	68.1 71.0		58.1	57.7 58.6	
	15–49				81.8	74.1 89.5		86.1	78.8 93.3					78.7	73.5 84.0		65.8	63.9 67.7	
	50–69				81.0	76.9 85.2		73.4	69.9 77.0					76.0	73.5 78.5		64.4	63.6 65.2	
	70–99				62.2	57.5 67.0		60.5	56.4 64.5					63.8	61.0 66.5		53.4	52.6 54.2	
Dukes' stage D	All ages				12.9	10.7 15.2		12.9	11.1 14.7					15.6	14.1 17.2		11.6	11.1 12.1	
	Age-standardised				11.9	10.6 13.2		12.8	11.6 13.9					15.7	14.7 16.8		11.6	11.3 12.0	
	15–49				26.3	19.2 33.3		21.2	15.4 27.1					21.8	16.4 27.2		18.3	16.3 20.3	
	50–69				18.4	14.9 21.9		18.1	15.4 20.8					21.4	18.9 23.9		16.0	15.1 16.8	
	70–99				6.4	4.6 8.3		8.2	6.5 10.0					11.1	9.4 12.8		8.0	7.4 8.5	
Missing stage	All ages				47.3	41.1 53.5		56.3	53.4 59.3					50.7	44.4 56.9		31.3	30.8 31.8	
	Age-standardised				45.8	41.1 50.5		56.8	54.7 59.0					53.6	48.8 58.4		31.2	30.8 31.6	
	15–49				81.9	69.8 94.0		83.1	73.7 92.4					92.9	74.5 100.0		58.2	56.2 60.2	
	50–69				66.2	57.0 75.4		73.4	69.6 77.3					74.8	66.2 83.5		44.8	43.9 45.7	
	70–99				34.5	26.9 42.2		49.1	45.6 52.7					42.7	35.3 50.1		24.6	24.0 25.1	
SEER Summary Stage 2000																			
All patients	All ages	69.9	69.2 70.6		62.8	61.1 64.5		58.1	56.8 59.5		63.0	62.1 63.8		68.1	67.1 69.1		54.9	54.6 55.2	
	Age-standardised	69.2	68.7 69.8		62.3	61.0 63.5		57.8	56.8 58.8		63.2	62.6 63.9		68.2	67.4 69.0		55.0	54.8 55.2	
	15–49	77.2	75.3 79.2		70.0	65.8 74.2		66.9	62.5 71.2		69.8	67.2 72.5		71.0	67.5 74.4		65.0	64.1 66.0	
	50–69	74.4	73.5 75.3		67.8	65.6 70.1		64.8	63.1 66.6		67.9	66.7 69.1		70.1	68.6 71.5		62.0	61.5 62.4	
	70–99	66.2	65.2 67.2		58.7	56.5 60.9		53.5	51.7 55.2		60.0	58.9 61.1		66.9	65.5 68.3		50.4	50.0 50.8	
Localised	All ages	92.5	91.5 93.4		91.9	89.9 93.8		89.6	87.5 91.7		90.9	89.4 92.5		92.8	91.7 93.9		87.0	86.6 87.5	
	Age-standardised	92.2	91.5 92.9		91.6	90.2 93.1		89.4	87.9 90.9		91.3	90.2 92.4		93.0	92.2 93.8		87.0	86.7 87.4	
	15–49	97.1	95.7 98.5		96.6	93.2 99.9		95.5	91.5 99.4		96.7	94.2 99.2		97.9	96.4 99.5		91.5	90.4 92.6	
	50–69	95.0	94.1 95.9		94.8	92.9 96.8		93.3	91.3 95.2		95.4	94.0 96.8		94.8	93.6 96.0		89.9	89.4 90.4	
	70–99	90.4	89.0 91.8		89.7	86.8 92.5		87.1	84.1 90.0		88.5	86.3 90.7		91.7	90.2 93.2		85.3	84.7 85.9	
Regional	All ages	74.7	73.6 75.7		70.4	67.4 73.5		67.6	64.9 70.3		77.2	76.1 78.3		68.8	66.8 70.7		58.5	58.0 59.1	
	Age-standardised	74.5	73.7 75.3		70.4	68.2 72.7		67.1	65.1 69.1		78.1	77.3 78.9		69.5	68.1 71.0		58.4	57.9 58.8	
	15–49	83.5	80.8 86.3		82.0	75.2 88.7		86.1	79.3 93.0		86.1	83.3 89.0		78.8	73.6 84.1		65.9	64.0 67.7	
	50–69	78.6	77.3 79.9		80.0	76.2 83.9		73.8	70.5 77.1		83.5	82.1 84.9		76.0	73.5 78.5		64.6	63.8 65.4	
	70–99	71.2	69.6 72.7		62.7	58.4 67.0		61.4	57.7 65.1		73.6	72.1 75.2		64.0	61.3 66.7		53.9	53.1 54.7	
Distant	All ages	20.1	18.7 21.4		12.9	10.6 15.1		12.9	11.0 14.7		14.2	13.1 15.3		15.7	14.1 17.3		11.6	11.1 12.1	
	Age-standardised	19.6	18.7 20.6		11.9	10.6 13.2		12.8	11.6 13.9		14.4	13.6 15.2		15.8	14.7 16.9		11.7	11.3 12.0	
	15–49	32.8	28.1 37.4		26.4	19.4 33.5		21.3	15.4 27.2		22.9	18.8 27.1		22.1	16.7 27.5		18.5	16.5 20.6	
	50–69	26.2	24.2 28.3		18.0	14.6 21.5		17.7	15.0 20.4		19.8	18.0 21.6		21.1	18.7 23.6		15.7	14.9 16.6	
	70–99	13.8	12.3 15.3		6.5	4.6 8.4		8.4	6.7 10.2		9.7	8.6 10.9		11.3	9.6 13.0		8.2	7.6 8.7	
Missing stage	All ages	64.2	61.9 66.6		32.3	25.4 39.1		56.0	53.0 59.0		56.7	53.7 59.7		50.6	44.4 56.9		31.3	30.8 31.8	
	Age-standardised	61.0	59.0 63.0		31.3	26.4 36.2		56.6	54.5 58.8		58.8	56.6 61.0		53.6	48.9 58.4		31.3	30.9 31.7	
	15–49	86.4	80.9 92.0		75.6	59.9 91.3		83.0	73.6 92.4		84.7	76.0 93.3		92.9	74.5 100.0		58.3	56.3 60.2	
	50–69	79.0	76.1 81.9		44.9	32.5 57.4		73.2	69.3 77.0		79.3	75.2 83.3		74.9	66.2 83.5		44.8	44.0 45.7	
	70–99	54.1	50.9 57.2		22.4	14.8 30.1		48.8	45.2 52.3		47.9	44.2 51.6		42.6	35.2 50.0		24.6	24.0 25.1	


¹ Australia: New South Wales.² Canada: Alberta and Manitoba.³ Sweden: Uppsala-Örebro and Stockholm-Gotland health regions.⁴ United Kingdom: Northern Ireland and all cancer registries in England.⁵ In Canada and Denmark we analysed patients diagnosed in 2004–7.

Supplementary Table IV. All-ages, age-specific and age-standardised three-year net survival (%) by stage at diagnosis, age and country for rectal cancer patients diagnosed during 2000–2007


		Australia ¹			Canada ^{2,5}			Denmark ⁵			Norway			Sweden ³			UK ⁴		
		NS (%)	95% CI		NS (%)	95% CI		NS (%)	95% CI		NS (%)	95% CI		NS (%)	95% CI		NS (%)	95% CI	
Dukes' stage																			
All patients	All ages				71.9	70.5	73.3	63.1	61.4	64.9	68.3	67.1	69.4	70.4	69.0	71.8	59.5	59.1	60.0
	Age-standardised				71.1	70.0	72.1	62.4	61.2	63.7	68.8	68.0	69.6	70.7	69.6	71.7	59.9	59.5	60.2
	15–49				79.4	76.1	82.6	72.0	66.7	77.3	78.0	75.0	81.1	74.3	70.0	78.6	69.7	68.3	71.0
	50–69				76.6	74.8	78.3	72.5	70.4	74.5	74.9	73.5	76.3	76.2	74.5	77.9	67.8	67.2	68.3
	70–99				65.8	63.6	68.0	53.7	51.1	56.2	62.4	60.8	64.1	65.8	63.7	67.9	52.5	51.9	53.1
Dukes' stage A	All ages				94.0	91.5	96.4	94.8	91.0	98.6	96.4	94.9	97.9	97.1	95.5	98.7	94.0	93.2	94.8
	Age-standardised				93.8	92.5	95.1	94.8	92.8	96.8	96.5	95.8	97.3	97.2	96.4	98.0	94.0	93.5	94.5
	15–49				97.5	96.3	98.7	98.0	96.4	99.5	98.7	98.0	99.3	98.9	98.2	99.6	97.7	97.0	98.3
	50–69				95.5	93.6	97.3	96.1	93.3	99.0	97.4	96.4	98.5	97.9	96.8	99.1	95.6	95.0	96.2
	70–99				91.9	88.6	95.2	93.3	88.3	98.3	95.4	93.5	97.3	96.4	94.3	98.4	92.3	91.1	93.5
Dukes' stage B	All ages				86.6	83.7	89.5	85.5	82.2	88.7	85.0	82.8	87.1	92.5	90.4	94.5	84.0	83.2	84.8
	Age-standardised				86.1	84.2	88.0	84.9	82.8	87.0	85.8	84.6	87.1	92.5	91.3	93.7	84.1	83.6	84.6
	15–49				96.1	93.7	98.6	94.7	91.5	97.9	96.2	94.7	97.7	93.0	89.7	96.3	91.9	90.9	93.0
	50–69				91.2	88.5	93.8	89.4	86.3	92.5	91.1	89.4	92.8	92.6	90.8	94.4	87.2	86.4	88.0
	70–99				80.7	75.7	85.7	80.7	75.8	85.6	80.0	76.7	83.2	92.3	89.3	95.2	81.0	79.8	82.2
Dukes' stage C	All ages				80.3	77.4	83.1	75.5	72.3	78.8	74.6	72.1	77.2	75.1	72.3	77.8	67.4	66.5	68.3
	Age-standardised				79.5	77.2	81.7	74.4	71.8	76.9	75.3	73.5	77.1	76.0	74.1	77.9	67.5	66.8	68.2
	15–49				87.1	81.6	92.7	80.6	71.5	89.7	87.7	82.9	92.4	87.9	81.8	93.9	75.8	73.4	78.2
	50–69				83.0	79.7	86.3	81.6	78.1	85.1	80.6	77.9	83.4	82.4	79.5	85.3	72.7	71.6	73.7
	70–99				75.2	70.4	79.9	67.0	61.6	72.5	67.9	64.0	71.9	67.4	63.2	71.7	61.1	59.8	62.5
Dukes' stage D	All ages				24.4	21.1	27.8	18.4	15.2	21.5	18.6	16.6	20.7	20.3	17.8	22.8	14.2	13.3	15.0
	Age-standardised				23.1	21.4	24.7	18.3	16.7	19.9	19.1	18.0	20.1	20.6	19.3	21.8	14.4	13.9	15.0
	15–49				30.6	26.4	34.8	25.1	20.8	29.4	26.0	22.7	29.2	27.1	23.2	30.9	20.3	17.9	22.7
	50–69				29.2	25.5	32.8	23.4	19.7	27.0	24.6	22.1	27.0	26.0	23.1	28.9	18.9	17.8	20.1
	70–99				16.4	13.4	19.4	12.3	9.6	15.1	12.7	10.8	14.5	14.0	11.7	16.3	9.1	8.3	10.0
Missing stage	All ages				70.4	67.6	73.1	54.7	51.0	58.5	64.0	61.5	66.4	41.5	36.4	46.6	38.1	37.3	38.8
	Age-standardised				70.4	68.4	72.4	58.3	55.8	60.9	65.0	63.3	66.7	47.5	43.5	51.4	40.7	40.1	41.2
	15–49				87.0	81.5	92.4	85.0	74.8	95.2	85.3	79.3	91.3	52.6	24.1	81.0	63.2	60.6	65.8
	50–69				82.2	79.0	85.3	74.6	70.1	79.2	79.2	76.2	82.2	61.0	52.2	69.8	52.4	51.3	53.6
	70–99				59.7	55.6	63.7	42.7	37.9	47.4	51.8	48.4	55.1	36.6	30.9	42.3	29.1	28.2	30.0
SEER Summary Stage 2000																			
All patients	All ages	72.1	71.2	73.0	72.2	70.8	73.7	63.6	61.9	65.4	68.2	67.1	69.3	70.1	68.7	71.5	59.6	59.2	60.1
	Age-standardised	71.1	70.4	71.8	71.4	70.3	72.5	62.9	61.6	64.2	68.7	67.9	69.6	70.4	69.3	71.4	60.0	59.6	60.3
	15–49	77.2	75.0	79.5	79.6	76.4	82.8	72.4	67.2	77.6	77.9	74.8	81.0	73.9	69.6	78.3	69.7	68.4	71.1
	50–69	76.8	75.7	77.9	76.8	75.0	78.5	72.8	70.7	74.8	74.8	73.4	76.3	75.9	74.2	77.6	67.9	67.3	68.4
	70–99	66.5	65.1	68.0	66.3	64.1	68.5	54.3	51.8	56.8	62.4	60.7	64.0	65.4	63.4	67.5	52.6	52.0	53.2
Localised	All ages	89.5	88.3	90.7	92.4	90.4	94.3	91.0	88.5	93.5	89.8	88.4	91.1	95.0	93.6	96.3	88.5	87.9	89.1
	Age-standardised	89.2	88.4	89.9	92.1	90.8	93.4	90.7	89.2	92.3	90.4	89.6	91.2	95.0	94.2	95.8	88.6	88.2	88.9
	15–49	96.7	95.7	97.7	98.4	97.3	99.6	97.7	96.0	99.4	97.8	97.0	98.6	95.6	93.7	97.6	94.8	94.2	95.5
	50–69	92.8	91.8	93.8	95.6	94.0	97.2	94.2	92.1	96.4	94.3	93.3	95.3	95.2	94.0	96.3	91.1	90.6	91.6
	70–99	85.4	83.4	87.4	88.3	84.9	91.7	87.2	83.4	91.1	85.9	83.8	88.0	94.7	92.7	96.7	85.9	85.0	86.8
Regional	All ages	77.8	76.3	79.3	78.7	76.0	81.3	74.8	71.7	77.9	74.6	72.4	76.8	75.1	72.4	77.8	67.3	66.5	68.2
	Age-standardised	77.7	76.6	78.8	77.9	75.9	80.0	73.8	71.4	76.2	75.6	74.1	77.2	76.0	74.1	77.9	67.4	66.8	68.1
	15–49	82.3	79.0	85.5	85.8	80.3	91.4	79.8	70.9	88.6	86.5	81.7	91.3	87.5	81.3	93.7	75.2	72.8	77.6
	50–69	81.9	80.2	83.5	81.6	78.4	84.8	80.7	77.3	84.0	81.8	79.4	84.2	82.4	79.5	85.2	72.6	71.6	73.6
	70–99	72.5	70.0	75.0	73.3	68.8	77.8	66.7	61.6	71.9	67.5	64.1	70.9	67.4	63.2	71.7	61.2	59.8	62.5
Distant	All ages	23.6	21.6	25.6	24.5	21.2	27.8	18.4	15.2	21.6	18.2	16.3	20.0	20.3	17.8	22.8	14.2	13.4	15.0
	Age-standardised	22.9	21.8	24.0	23.2	21.5	24.8	18.5	16.9	20.0	18.7	17.7	19.7	20.6	19.4	21.9	14.5	14.0	15.0
	15–49	30.8	27.6	34.0	31.6	27.5	35.8	26.2	22.0	30.5	26.5	23.5	29.5	28.4	24.7	32.1	21.4	19.1	23.7
	50–69	28.5	26.2	30.8	29.0	25.4	32.7	23.3	19.6	26.9	23.8	21.6	26.1	25.9	23.0	28.7	18.8	17.7	19.9
	70–99	16.1	14.2	18.1	16.4	13.3	19.4	12.4	9.6	15.1	12.1	10.5	13.8	14.0	11.7	16.3	9.1	8.3	9.9
Missing stage	All ages	69.0	66.4	71.7	69.2	66.4	72.1	54.6	50.9	58.3	47.0	42.2	51.8	41.4	36.2	46.5	38.0	37.3	38.8
	Age-standardised	66.8	64.7	69.0	68.8	66.7	70.9	57.5	54.9	60.1	55.9	52.4	59.4	47.0	43.1	50.9	40.1	39.5	40.6
	15–49	88.6	83.7	93.6	86.4	80.8	92.0	85.1	75.0	95.2	84.1	70.8	97.4	52.8	24.2	81.3	63.2	60.6	65.9
	50–69	80.5	77.2	83.8	81.2	78.0	84.5	74.6	70.1	79.2	78.3	71.3	85.2	61.0	52.2	69.8	52.5	51.3	53.6
	70–99	56.4	52.3	60.6	58.4	54.2	62.5	42.5	37.7	47.2	32.2	26.5	38.0	36.5	30.8	42.2	29.0	28.1	29.9

¹ Australia: New South Wales.² Canada: Alberta, British Columbia and Manitoba.³ Sweden: Uppsala-Örebro and Stockholm-Gotland health regions.⁴ United Kingdom: Northern Ireland and all cancer registries in England except the Thames Cancer Registry.⁵ In Canada and Denmark we analysed patients diagnosed in 2004–7.


Supplementary Figures



Supplementary Figure 1. Proportions of colon cancer patients with missing data on stage (upper figure) and cumulative stage distribution (lower figure) by age at diagnosis and country, Dukes' (left) and SEER Summary Stage 2000 (right).



Supplementary Figure 2. Age-standardised three-year net survival from colon cancer by stage at diagnosis and country using known stage and imputed stage, Dukes' (upper figure) and SEER Summary Stage 2000 (lower figure).



Supplementary Figure 3. Age-standardised three-year net survival from rectal cancer by stage at diagnosis and country using known stage and imputed stage, Dukes' (upper figure) and SEER Summary Stage 2000 (lower figure).